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Abstract 
Background: Sleep Disordered Breathing (SDB) is a leading cause of morbidity world wide. 
Its prevalence increases with age. Due to the demographic changes in industrial societies, 
pulmonologists and sleep physicians are confronted with a rapidly growing number of elderly 
SDB patients. For many physicians it remains unclear how current guidelines for SDB 
management apply to elderly and frail elderly patients. The goal of this consensus statement 
is to provide guidance based on published evidence for SDB treatment in this specific patient 
group. 
 
Methods: Clinicians and researchers with expertise in geriatric sleep medicine representing 
several countries were invited to participate in a task force. A literature search of Pubmed 
from the last twelve years as well as a systematic review of evidence of studies deemed 
relevant was performed. 
 
Results: Recommendations for treatment management of elderly and frail elderly SDB 
patients based on published evidence were formulated via discussion and consensus. 
 
Conclusions: In the last twelve years, there have been surprisingly few studies examining 
treatment of SDB in older adults and even fewer in frail older adults. Studies that have been 
conducted on the management of SDB in the older patient population were rarely stratified 
for age. Studies in SDB treatment which did include age stratification mainly focused on 
middle aged and younger patient groups. Based on the evidence that is available, this 
consensus statement highlights the treatment forms which can be recommended for elderly 
SDB patients and encourages treatment of SDB in this large patient group. 
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Summarizing sentence: This article on the treatment of SDB in elderly patients gives an 
overview of the research done in the field and based on it clinical guidelines. 
 
INTRODUCTION 
 
The world today is facing an unprecedented aging of the population. According to the WHO, 
the number of people aged 65 years or older is projected to grow from an estimated 524 
million in 2010 to nearly 1.5 billion in 2050, with most of the increase in developing countries 
(1).  
The prevalence of sleep disordered breathing (SDB) in this age group, based on a definition 
of an apnea-hypopnea index (AHI; the number of apneas and hypopneas per hour of sleep 
of at least 10), is over 20% in various epidemiological studies (2,3,4). In frail elderly patients, 
prevalence rates reach as high as 60% (5). These data suggest that in the future, sleep 
medicine health professionals will be asked increasingly to evaluate the need to treat SDB in 
elderly patients over 65 years of age. 
 
This aged patient group can differ from younger or middle aged patients with SDB in many 
ways. In fact, this large and growing population is a highly diverse group, as the aging 
process varies from one individual to another. Some individuals age very well without serious 
disease and function perfectly in daily life, i.e., they experience “successful aging” (6). Other 
older adults have many comorbidities, several handicaps and several serious diseases and 
consequently are frail. This phenomenon is named “pathological aging”. Yet other individuals 
are between the two categories representing the “usual aging” that may be associated with 
chronic but stable comorbidities but without significant dysfunction in daily life. 
 
SDB, in older populations as in younger ones, is associated with serious outcomes including 
stroke (7,8,9), occult nocturnal hypertension (10), open angle glaucoma (11), falls with 
fractures (12), impaired quality of life (13), decreased pain tolerance (14), frailty (15) and 
mortality (16,17,8,9). These potentially serious outcomes of SDB in elderly patients imply that 
treatment for SDB may be at least as necessary as in younger and middle aged SDB 
patients. Effective treatment of the disorder has been associated with major improvements in 
pain tolerance (14), in risk of falls (12), stroke (9) as well as diminished risk of cardiovascular 
morbidity and mortality (17). In view of these considerations it should not be surprising that 
untreated SDB in older adults is associated with significant medical costs (18). The 
potentially serious outcomes of SDB in elderly patients imply that treatment for SDB may be 
at least as necessary as in younger and middle aged SDB patients. 
 
Despite the high prevalence of SDB in the older populations, the condition is frequently 
unrecognized and undiagnosed even in geriatric settings (18,19). Unfortunately, many older 
patients who do seek medical attention for SDB are dismissed as having no significant illness 
without formal assessment. At least three factors underlie the lack of recognition of SDB in 
older adults: 1. Clinical presentation of the disorder may often be atypical (5, 20, 21) and 
history taking and the interpretation of signs and symptoms related to SDB are extremely 
difficult (22).  2. Health professionals are not well prepared to screen and manage sleep 
problems especially in older adults. The disparity between a high prevalence of undiagnosed 
OSA (Obstructive Sleep Apnea) in the population and the low level of clinical recognition has 
been recognized in different patient groups (5; 20, 21). 3. Sleep laboratories are not easily 
accessible to many frail older adults living in nursing homes and long term care units. 4. We 
do not know in elderly, what is the limit between physiological and pathological in terms of 
number of sleep disordered breathing. 
 
Regarding the latter issue, the low diagnostic rate of SDB in elderly might change with the 
changing diagnostic policies for SDB by healthcare insurances and providers. For example, 
in lieu of sleep laboratory based polysomnography (PSG), home sleep testing may now be 
covered in many countries. Regardless of which test is performed, older patients should be 
evaluated with a comprehensive geriatric assessment (23, 24). Nevertheless, treatment 
outcomes regarding clinical symptoms, for example excessive daytime sleepiness, might be 
different in the different age groups as shown in the Stuart/Florida cohort of the Sleep in 
Primary Care Study (20). 
Although in the past decades and more recently there have been several reviews and meta-
analyses that have helped define therapeutic management for OSA, (25, 26, 27, 28, 29) the 
majority of these have focused on middle-aged populations. Given the uncertainty regarding 
effects of OSA treatment in elderly populations, we undertook a consensus process to 
analyze all treatment studies in older populations with SDB performed in the last twelve 
years. Our goal was to develop evidence-based practice recommendations. This paper is an 
outcome of that process. 
 
METHODS 
 
On invitation by the Geriatric Assembly of the German Sleep Society (DGSM) and individual 
members (N. Netzer, F.Almeida) of the Assembly Sleep and Respiratory Neurology of the 
American Thoracic Society (ATS), eleven experts in geriatric sleep medicine formed a panel 
representative of the diversity of opinions from the Americas and Europe and were members 
of the several societies involved in guidelines for sleep disordered breathing therapy, namely 
ATS and European Respiratory Society (ERS) as well as American Academy of Sleep 
Medicine (AASM), the Sleep Research Society (SRS) and the European Sleep Research 
Society (ESRS). In addition, the group aimed to cover different fields involved in the 
treatment of SDB, namely psychiatry, pulmonary, geriatric medicine, dentistry, neurology, 
behavioral science, and airway physiology. 
 
The panel met for the first time in Berlin, Germany, December 2012 and thereafter on several 
other occasions at various sites in 2013-2015, and decided on the structure of a systematic 
review of publications covering therapy of SDB in older patients. After much discussion, there 
was consensus to define “older” as aged 65 years and over as this age is the most frequently 
used cut-off for elderly in the scientific literature. Papers were only included in this review if 
the population studied included patients with a mean age of 65 or older, a majority of patients 
65 years of age or older, or included older adults of 65 years and older in their sample and 
gave the results stratified by age (i.e., were results in the older adults the same or different 
than in the younger adults). 
 
Pubmed/Medline publications from the last 12 years until May 31, 2015 were searched with 
keywords of “sleep disordered breathing”, “sleep apnea”,”OSA”, “OSAS”, OSAHS”, “central 
sleep apnea”, “therapy”, “aged”, “elderly. This resulted in a total of 1740 publications with 
abstracts in English language. A team of two panel members reviewed the literature to 
examine how many studies were primarily on older adults and fulfilled the above described 
inclusion criteria. In a second step, a team of two other panel members performed a second 
screening of the 1740 abstracts based on the sole criteria of whether the publication dealt 
with SDB therapy in the geriatric age group. This resulted in a total of 178 publications (all in 
English language) meeting criteria.  
 
The 178 full papers were then distributed to five teams of two panel members each. The 
scoring teams were formed with the following subspecialties within the panel: Noninvasive 
ventilation therapy, dental and oral appliance therapy, cardiologic and surgical therapy, 
supplemental oxygen therapy and alternative treatment options including drugs. 
 
Each paper was evaluated for whether it met the inclusion criteria and each was scored for 
the evidence level based on the GRADE working group into four evidence levels: “High”, 
“Moderate”, “Low” and “Very Low” (30 ) and parallel each paper was scored according to the 
evidence scoring of the Scottish Intercollegiate Guidelines Network grading (SIGN, see table 
1) (31). SIGN was chosen parallel to GRADE to determine evidence levels of studies 
because it ranks original randomized controlled studies highest, before metanalyses, which 
seemed to be more appropriate for the development of principle of practice parameters than 
the usual evidence grading, which ranks metaanalyses in the highest position, and because 
it gives in addition to GRADE (four levels) a higher differentiation of evidence of papers into 
eight levels (1++ - 4). In addition a Jadad score was assigned to each study to assess the 
level of possible bias of each study (see table 2) (32).  
For the clinical recommendations or guidelines the GRADE ranking for “strong” or “weak” 
from the GRADE working group has been applied (30).  
 
Each team created a table of publications that fulfilled the inclusion criteria and wrote the 
corresponding section for this publication. When there were insufficient numbers of 
publications meeting inclusion criteria, results from publications in younger adults were 
summarized, with the understanding that those results may or may not apply to the elderly 
and the frail elderly. Each team also provided recommendations for the principle of practice 
parameters within their subspecialty. The final recommendations of the expert consensus for 
each treatment are presented at the end of each chapter.  
 
EVALUATION  AND CLINICAL RECOMMENDATIONS 
 
Positive Airway Pressure (PAP) and Servoventilation Treatment  
It is well documented that OSA is well treated with PAP. There have been many studies on 
the effect of treating OSA on outcomes other than apnea-related symptoms, such as heart 
failure, hypertension, diabetes, etc.; however, few of these studies have been conducted on 
older adults or in frail elderly. Only 29 papers met the inclusion criteria and these 29 were 
reviewed, evaluated and are presented in Table 3. Two of these studies reviewed stratified 
the results by age and five papers represented different components of a single clinical trial. 
 
The majority of the studies (n=21) evaluated populations with medical co-morbidities more 
prevalent in older adults (e.g. dementia, Parkinson’s disease, stroke, heart failure, COPD), 
and the main outcomes were the effect of PAP treatment on either apnea or on some aspect 
of that co-morbidity. 
 
As can be seen in Table 3, the evidence levels of these studies ranged from high of 1++ (one 
study) (33) to low of 2- . Only 13 were RTCs (Randomized Controled Trials), with the rest 
being observational in nature. The Jadad score for 20 publications were in the 0-3 range 
suggesting a higher risk of bias; eight were scored in the 4-5 range suggesting a lower risk 
and a higher quality study. Sample sizes ranged from a handful to over 4000. 
 
Heart Failure or Cardiovascular Disease  
 
Nine of the studies had a primary outcome of some form of heart disease, hypertension or 
renal disease measures (34-42). Results of these studies suggested that CPAP (Continuous 
Positive Airway Pressure) or ASV (Adaptive Servoventilation)  treatment of the OSA and/or 
CSA (Central Sleep Apna) resulted in overall improvement in the primary outcome 
measures. These results were often compared to either no treatment groups or groups of 
non-compliant PAP patients. Most of these studies however were observational cohort 
studies with only three RCT (33, 34, 41). Preliminary results from a major RCT, the SERVE 
HF study, have been reported recently (43) that suggest that ASV specifically may have 
detrimental effects in chronic heart failure (CHF) patients with an ejection fraction of ≤45% 
across a broad age range who have predominantly central sleep apnea, so the value of this 
particular type of positive airway pressure delivery in some elderly patients with heart failure 
remains uncertain. 
 
Overlap Syndrome 
Although one might suspect that the overlap of OSA and COPD (Chronic Obstructive 
Pulmonary Disease) should be very common in the elderly OSA patient group, because 
COPD is very common in elderly patients, only one study was found which fulfilled the 
inclusion criteria. But this high quality cohort study not only had a large elderly cohort in an 
overlap patient group, it was also stratified for age (43). The retrospective analysis of almost 
800 sleep laboratory patients revealed that the prevalence for the overlap syndrome is 
significantly higher in elderly OSA patients compared to younger and middle aged patients 
and that auto CPAP and bilevel CPAP lead to a significant improvement of blood gases over 
a longer period of time in comparison to patients who were non compliant to CPAP or 
patients who had COPD alone. 
 
Stroke 
Three studies either included stroke patients as the full sample or had stroke as the primary 
outcome (45, 46, 47), and one study had mortality due to stroke as a secondary outcome 
(46). Two of the four studies were RCT with untreated participants as the control groups 
(45,46). For those studies with stroke or vascular events as the outcome, all showed fewer 
events in the PAP-treated group. The one study examining the effect of PAP on apnea–
related symptoms in stroke patients found no improvement (47).     
 
Dementia 
Seven studies included patients with either Alzheimer’s disease (AD) (48-53) or Parkinson’s 
disease (PD) (53), and three of these examined the effect of PAP on cognition (48, 52, 53). 
The results suggested that PAP treatment in patients with AD or PD results in good 
adherence (see Adherence section below), reduced apnea-related symptoms (daytime 
sleepiness) and AHI , and led to deeper sleep (45-49,51). One study found that 3-weeks of 
PAP treatment resulted in some improvement in cognition, but a 3-week comparison to sham 
CPAP was underpowered (48). Two showed that long term use of PAP in AD patients 
resulted in slower cognitive deterioration (52,53).    
 
Effect on Sleep Apnea 
Nine studies either focused on the effect of PAP on OSA-related symptoms ( daytime 
sleepiness, oxygenation) and AHI or included these outcomes as part of their studies 
(35,40,42,45,47,50,52,54,55). Of these nine, eight were RCT and one was a controlled open-
study without randomization. Seven of the nine studies showed that PAP treatment of OSA 
resulted in improvement of breathing or of sleep architecture and daytime sleepiness 
(35,42,45,50,52,53,55). One study found that there were no significant improvements in any 
of the outcome measures including daytime sleepiness (47). 
 
Adherence 
Five studies focused on PAP adherence (52, 55, 56-58). An additional four studies reported 
adherence although it was not an outcome variable (42, 45, 47, 59). Of these nine studies, 
five were RCTs. Only three studies actually reported hours of PAP use (49, 55, 59), and this 
included one in patients with AD who wore the PAP for an average of 4.8 hours (49). These 
authors also found that more depressive symptoms were associated with worse adherence 
(49). In 6 papers, the authors all reported that adherence was high and was often associated 
with greater improvement in the outcome measures, but did not report actual hours of use. 
One study reported more modest usage (medians of 1 hr 52 mins to 2 hrs 22 mins) but did 
not correlate results with outcomes (55). One study reported that acceptance rates were 
lower in older patients than younger patients, but there was no difference in the number of 
hours used within compliers (56). 
 
Mood 
Five studies examined the effect of PAP treatment on mood or depression, all of which were 
RCTs (47, 49, 52, 55, 60), but two were from the same population of subjects (acute vs. long 
term use of PAP)(49,52). Both these studies showed improvement in mood with short- and 
long-term use. One study found no change in depression scores with PAP use (47), but 
another did (55).  
  
Cognitive Function in elderly Patients without Dementia 
The PREDICT multicenter study reported that a lower daytime sleepiness score and reduced 
risk factors for cardiovascular diseases in elderly CPAP users was acheived at the same cost 
as best supportive care; however neither CPAP nor best supportive care had an influence on 
mood and cognitive function (60). In contrast, the PROOF study found a significant 
improvement in cognitive function (assessed with different memory tests) after CPAP therapy 
in OSA patients with no AD or PD (59). The recent RCT from the Spanish Sleep Network 
noted evidence of improvement in neuropsychological functions on several different 
measures of cogntintion (55). 
 
Quality of Life and Cost Effectiveness 
Four studies had quality of life as one of main outcomes of PAP therapy in elderly patients 
(55, 58, 61, 62). One of the studies used the Sleep Apnea Quality of Life Index (SAQLI) and 
found a significantly better quality of life in the 21% who used CPAP (58). Another study 
reported substantial effect size differences in all quality of life measures over time in a CPAP 
group realtive to controls (55). One study was gender oriented and concentrated on sexual 
function and male health in older men with OSA (62). The authors found a better subjective 
male health quality in the CPAP users versus a control group without CPAP, and this result 
was independent of testosterone levels. 
 
Summary 
In summary, studies of PAP treatment of SDB in the elderly primarily showed improvement in 
variables of SDB (e.g., AHI, daytime sleepiness) as well as consequences of SDB including 
comorbidites and psychosocial factors. While studies of frail elderly (i.e., those with AD or 
PD) were well-controlled, the majority came from the same laboratory and the AD studies 
were primarily from the same cohort; therefore replications are needed. In addition, many of 
the studies were small sample sizes and did not have high evidence levels. Larger, 
randomized, controlled studies are still needed in older adults and the frail elderly.  
 Recommendations on the expert consensus level:  
1. PAP should be used routinely for the treatment of SDB in older persons and in frail 
elderly, particularly those with stroke but without major heart failure with an ejection 
fraction ≤45%. GRADE: Strong 
2. While additional randomized controlled trials are needed in patients with AD and PD 
as well as other frail elderly, these patients do tolerate PAP and treatment should be 
considered. GRADE: Strong 
3. PAP leads to a significant improvement of oxygenation in patients with SDB and 
COPD (Overlap Syndrome) and should be routinely used in these patients. More 
studies are needed if additional oxygen further improves results. GRADE Weak  
4. Due to the results of the large RCT “SERVE HF” and the following recommendations 
of all major pulmonary and sleep societies to abstain from servoventilation treatment 
in patients with heart failure (NYHA 2-4) with an ejection fraction ≤45% no 
recommendation can be given regarding PAP treatment for this patient group until 
further trials have shown that CPAP in comparison to servoventilation has no 
negative outcome on mortality. 
 
 
Dental Treatment 
Four articles met the inclusion criteria and were reviewed and evaluated. All four had an 
evidence level of 2- and are presented in Table 4. Only one of these articles had oral 
appliance treatment as its topic and this study also stratified results of a larger cohort for age. 
Three articles assessed denture wearing at night and all three had an elderly patient group 
and did not stratify by age. 
 
Oral Appliance Treatment 
Currently, the primary treatment for OSA is PAP, however, some patients are unable to 
tolerate and comply with PAP on a long-term basis. Oral appliances are now widely used for 
the treatment of snoring and mild-to-moderate OSA as primary therapy and for severe OSA 
as an alternative for patients who are unwilling or unable to tolerate PAP (63). 
 
Oral appliances can be divided into two major types: 1) those that reposition the mandible 
forward, the mandibular advancement splints (MAS) or mandibular advancement device 
(MAD), and 2) those that hold the tongue forward, the tongue retaining devices (TRD) (64). 
In a recent review, a randomized control trial comparing MAS to PAP treatment confirmed 
that PAP is superior in reducing the AHI (65). Despite the greater efficacy of PAP in the 
reduction of apnea, both treatments equally improved quality of life, neuropsychological 
measurements, cardiovascular disease markers and mortality rate (66-68). This comparable 
effectiveness of PAP and MAS has been hypothesized to be related to a greater adherence 
to MAS when compared to CPAP.   
 
Despite having currently more than eleven randomized control trials comparing MAS to 
CPAP, a vast literature on MAS efficacy, and many studies including patients older than 65 
years in their sample, there is only one study to our knowledge which has evaluated this type 
of treatment separately for the elderly population. Marklund and collaborators  described in a 
retrospective study the follow-up of 33 patients older than 65 years (mean age 68.5±1.7) with 
and without the use of a MAS (69). They found a statistically significant improvement in the 
AHI for the group using a MAS (AHI 22.3±16.7 at baseline and 10.4±12.9 with MAS). 
  
While MAS shows an overall 50-60% chance of being able to reduce the AHI to normal 
levels(70), there are various studies attempting to identify predictors of success. While some 
studies found that an increase in age was negative predictor of MAS success (i.e. the older 
the patient the less likely to achieve treatment success), these studies have assessed mainly 
patients with an average age of 44 to 49 years of age (65, 71-75). One study, which included 
about 5% of patients over the age of 65, did not find age as a predictor of treatment success 
in either men or woman (76). There is, therefore a lack of studies focusing on this population 
and further studies are required to assure the efficacy of MAS for the elderly population. 
 
Another important point in the utilization of MAS is that there is a need of a minimum of 8 to 
10 teeth per arch and good/constant dental hygiene and these characteristics are not always 
the case in the elder and/or frail population. In these cases, the oral appliance of choice is 
the TRD. This appliance can be used over dentures and/or reminiscent teeth. Still there is a 
need for manual coordination and likely the lack of tongue tremor to ascertain the proper 
insertion and retention of the TRD every night. One study comparing the TRD to MAS found 
similar efficacy but a higher adherence rate to MAS over TRD on dentate (non-denture user) 
(77). Previous studies also found similar TRD efficacy. Interestingly these studies mostly 
assessed dentate individuals younger than 65 years of age (78-82). The literature on TRD is 
limited and none of the studies assessed this type of treatment for the elderly or edentulous 
population.  
 
Denture Wearing at Night 
The incidence of edentulism (loss of teeth or no teeth) has dropped over the past decades, 
with a 10% decline in every decade. Despite this decline, it has been estimated that 24% of 
individuals aged 55 to 65 years will need 1 or 2 dentures in 2020, while 28% of adults 
between 65 and 75 and and 41.5% older than 75 years will need denture services in 2020 in 
the United States (83). Tsuda and collaborators, using the Berlin questionnaire, found that 
42% of patients from an edentulous clinic showed a high probability of having OSA (84). 
Case reports also suggest edentualism as an OSA risk factor (85). 
 
Dentists generally recommend the removal of dentures during sleep since constant wear is 
believed, though with small long-term scientific evidence, to increase denture irritation, 
stomatitis and bone resorption. Bucca and collaborators therefore assessed the impact of 
wearing dentures during sleep on 2 consecutive nights in 48 patients (86). They found that 
48% of patients had OSA while wearing their dentures during sleep and this incidence rose 
to 71% if the individuals removed their denture to sleep. Similarly, Arisaka and collaborators 
found that wearing dentures during sleep improved the apneas and hypopneas in 70% of 
individuals but interestingly, 14% showed a significant increase in the AHI while wearing 
dentures (87). This controversial aspect was confirmed by Almeida and coworkers who 
conducted a randomized trial and found an aggravation of OSA while wearing dentures (88).  
This worsening of OSA was predominantly related to individuals with mild OSA sleeping in 
the supine position (88).  
 
Summary 
In summary, larger randomized controlled trials are needed to better understand the role of 
dentures in the worsening or improvement of OSA. It is important to assess these individuals’ 
characteristics while wearing and not wearing their dentures during polysomnography. 
Simple measures, such as sleeping with dentures, may play an important role in improving 
OSA and decreasing the requirement of treatment for this population. 
 
Recommendations on the expert consensus level: 
1. A clear recommendation for MAS, MAD or TRD as first line treatment in mild to 
moderate SDB can not be given at this point in time as only one study stratified the 
particiants by age. Further prospective clinical trials with higher evidence levels are 
needed in the elderly with SDB. 
2. In case of CPAP failure, MAS, MAD or TRD treatment is recommended in elderly 
SDB patients as second line treatment after full assessment of a dental status. 
GRADE: Weak 
3.  A recommendation towards full/partial denture wear at night or non full/partial 
denture wear at night in elderly and frail elderly with SDB cannot be given at this point 
of time as the results of the few clinical trials are too controversial to reach a 
conclusion.   
 
Cardiac Resynchronization, Atrial Overpacing, Surgical Treatment, Upper Airway 
Stimulation, and Weight loss 
Twelve papers for this treatment chapter met inclusion criteria, were reviewed and evaluated 
and are listed in Table 5. Two of these twelve studies (one pacemaker and one bariatric 
surgery) were stratified for age. The evidence level ranged from 1+ to 2- with six publications 
about pacemaker therapy having an evidence level of 1+ (see Table 5). 
 
Heart Pacemakers – Cardiac Resynchronisation Therapy (CRT) 
Pacemakers are very common in the elderly. Approximately 130,000 US citizens 65 years 
and older receive a pacemaker every year. According to a publication by the Grenoble work 
group, the prevalence for sleep apnea confirmed by PSG in pacemaker wearers was 59%, of 
which 21% had severe sleep apnea defined by an AHI > 40 (89, 90). According to several 
studies with sufficient evidence levels of 2 or more, CRT with the pacemaker per se reduces 
apneic events by increasing the cardiac output, reducing atrial afterload and therefore 
periodic breathing. According to a controlled open-study with 15 patients, mean age 67 
years, CRT reduced apneic events and also reduced the increased pulmonary artery 
pressure (91). Three trials showed that CRT improves all types of apneic events significantly. 
In all these trials, CRT was also compared to atrial overpacing in a cross-over fashion (92-
94). 
 
Atrial Overpacing (AOP) 
The physiologic concept behind putting the pacemaker on a higher frequency (overpacing) 
than with CRT is that the total stroke volume over time increases further and therefore the 
atrial afterload is even lower, leading to a further decrease in apneas. A recent randomized 
cross-over trial showed in 28 patients with a mean age of 77,9 years that an overpacing of 20 
beats per minute (bpm) over the sensored mean heart rate resulted in a significant reduction 
of central events (95) (see Table 5). The only age stratified study which compared CRT and 
AOP in 15 subjects, mean age 74, found that  AOP resulted in a higher reduction of all apnea 
events, but not hypopneas, compared to lower fixed heart rate, mean AI 18 with AOP vs 24 
with fixed lower rate coming from a mean baseline of 35. The age stratification showed a 
stronger effect at lower ages (94).  
 
Only two trials claimed that CRT and AOP reduced both central and obstructive events with 
slight favor towards AOP (92, 94). But several studies with sufficient evidence level had 
contrary results (93, 96, 97). All the studies had a small number of total subjects and often 
less than 10 patients aged over 65. The only study with a larger number of patients and 
patients all over 65 years suggested a positive effect of AOP on central, but not obstructive 
events (95). 
  
Two studies investigated specifically obstructive events and OSAS. Both, with less than 20 
patients, found that AOP had no effect on obstructive events (98, 99). Because of the high 
prevalence of pacemaker implementation in the higher age group, there are a higher number 
of publications meeting basic criteria and higher evidence levels in comparison to the overall 
role this form of treatment plays among SDB treatment. This has to be taken into account 
when interpreting the following recommendations on the expert consensus level.  
 
Surgical ENT (Ear Nose Throat) Procedures/Upper Airway Stimulation 
Within the 1740 publications screened, there were no articles meeting the inclusion criteria. 
This might be related to avoidance of elderly patients who might have a higher peri- and post 
operational risk as well as to a more sophisticated selection process in order to achieve 
higher success rates and better long term results of surgical treatment for OSA and heavy 
snoring. A good example for this is the actual hypoglossal nerve stimulation (HNS) study of 
the STAR Trial (Stimulation Treatment for Apnea Reduction), where selection criteria for 
younger, non-obese OSA patients without concentric collapse in the velopharynx have been 
set at the highest level to avoid failure of the trial as has happened in other HNS trials (100). 
Less than a handful of patients in the STAR trial were over 65 years old. 
 
Surgical Treatment for Weight Loss 
One publication met the inclusion criteria of age stratification. This study looked 
retrospectively into a group of 5290 severely obese subjects with OSA, all of whom received 
surgery with a gastric banding for weight loss. The authors claimed that in the 216 geriatric 
patients (184 females) aged older than 65 years of the 5290 patients total, the operation was 
successful in all, bringing the AHI at a level below 10 (101). The retrospective analysis has a 
lower evidence level and the results should be replicated in prospective trials before a 
statement can be made regarding gastric banding surgery in geriatric patients with SDB. Two 
publications just missed the inclusion criteria but dealt specifically with an older patient group 
(>60 years) and had a higher evidence level (102, 103). In both publications the effects of 
weight loss after laparoscopic Roux-en-Y gastric bypass (LRYGB) was evaluated in the older 
patient group, all of whom had been severely obese before surgery. A total of 300 patients 
had a reduction of their sleep apnea and AHI and further comorbidities related to their severe 
obesity without major peri-operation complications. LRYGB has opened the possibility of 
bariatric surgery for older severely obese persons, for whom more invasive bariatric surgery 
has been too high of a risk before. LRYGB might become a major supportive treatment for all 
comorbidities of obesity including SDB in the near future. 
 
Dietetic Weight Loss Treatment 
None of the screened publications on dietetic weight loss therapy for SDB treatment met 
inclusion criteria. Therefore no statement can be made. 
 
Recommendations on the expert consensus level: 
1. In patients with heart failure, atrial fibrillation and central apneas there is evidence 
that pacemaker implement can alleviate central apneas and periodic breathing 
respectively. In such patients pacemaker implement can be recommended on an 
expert consensus level. GRADE:Strong 
2. The evidence level is too low to give a recommendation in regard of favoring the type 
of pacemaker modus. Larger randomized controlled cross over trials are needed here 
in the future to make a statement. 
3. No surgical ENT procedure can be recommended at this time as therapy for geriatric 
and frail geriatric patients with OSA, as there is no evidence of success in the elderly 
patient groups. Larger trials in the future should include age stratification.  
GRADE:Weak 
4. Due to new noninvasive surgical methods with laparoscopic Roux-en-Y gastric 
bypass (LRYGB), for which several-year outcome data show some evidence of 
clinical success in older patients, this form of bariatric surgery can be considered as 
supportive treatment in multimorbid (not only sleep apnea) severely obese patients 
(BMI> 40) in the intermediate elderly age group between 60 and 70yrs. with SDB. 
PAP and other treatments should be adapted to the post OP status. GRADE:Weak 
 
Positional Treatment and Drug Therapy 
Two papers on positional treatment and seven on drug treatment met inclusion criteria, were 
reviewed and and evaluated. They are presented in Table 6. The evidence levels ranged 
from 1+ to 3 with two RTC drug trials reaching 1+. One of the drug studies was designed as 
a negative study and was age stratified.  
 
Positional Therapy  
The severity of sleep-related breathing disorders may vary considerably from night-to-night, 
depending on body position (104,105), although some data have suggested night-to-night 
variability in elderly persons occurs independently from position (106). In particular, the 
supine body position is associated with a two-fold or more increase in the number of 
respiratory events in those patients with position-dependent sleep apnea. Positional therapy 
includes a wide range of methods aimed at preventing the patient from sleeping in the supine 
position, including pillows, vests, tennis-balls, positional alarms, and more. Case reports 
have documented the potential utility for positional therapy (104). 
Positional therapy has been included in the recent clinical guideline for the treatment of 
obstructive sleep apnea by the Adult Obstructive Sleep Apnea Task Force of the American 
Academy of Sleep Medicine (107). The guideline identified positional therapy as an effective 
secondary therapy or a supplement to primary therapies for patients with OSA that have a 
low AHI in the non-supine position. Nevertheless, two recent reviews of positional therapies 
highlighted the fact that long-term compliance for positional therapy remains an issue (108) 
and that more high-quality research is needed to evaluate the effectiveness of this therapy 
(109) 
 
One study described one night use of a specifically designed pillow to avoid the supine 
position in 22 patients, 9 of whom were older than 65 years (110). This study compared 
nocturnal respiratory parameters between a baseline night and a night with the supine-
avoiding pillow in patients with mild to severe obstructive sleep apnea. In the paper the 
individual subject’s data are given in a table which allowed us to identify the 9 patients that 
were between 67 and 73 years old. In these older patients the respiratory disturbance index 
decreased from an average of 20 (SD=9) to 7 (SD=4) and minimum SaO2 during the night 
rose from 85 (SD=7) to 89 (SD=4).  
 
Another study that did not meet the inclusion criteria, but did evaluate the use of a vest for 
one night in 12 patients between 37 and 76 years of age with in-patients with positional 
obstructive sleep apnea (111). Although the authors did not stratify by age, they did report 
that the eldest patient did not improve with this treatment. 
 
In contrast two recently published studies showed a significant effect for positional therapy 
with the new sleep position trainer in subjects of all ages. They included several patients > 65 
yrs of age, but the average age was around 50 years and therefore did not meet inclusion 
criteria.There was no stratification for age (112,113). 
 
 
 
Drug Therapy 
There has been no drug therapy recommended for the treatment of SDB. For the treatment 
of central sleep apnea, evidence-based, recent guidelines found limited supporting evidence 
for acetazolamide and theophyilline after optimization of standard medical therapy and if 
positive airway pressure therapy is not tolerated (114). In addition, the guideline stated that 
zolpidem and triazolam may be considered for the treatment of primary central apnea only if 
the patient does not have underlying risk factors for respiratory depression.  
 
For the treatment of OSA, the 2006 practice parameters for medical treatment of OSA 
evaluated but did not recommend selective serotonin uptake inhibitors (SSRIs), protriptyline, 
aminophylline, theophylline, or estrogen therapy based on the lack of sufficient treatment 
efficacy for OSA (115). While short-acting nasal decongestants were not recommended, the 
guidelines concluded that topical nasal corticosteroids may be a useful adjunct to primary 
therapies in OSA patients with concurrent rhinitis. In addition, modafinil was recommended 
for the treatment of residual excessive daytime sleepiness in patients with sleepiness despite 
effective PAP treatment and without other identifiable causes for the sleepiness. These 
recommendations concur with the most recent, 2009 Clinical Guideline for the evaluation, 
management and long-term care of obstructive sleep apnea in adults (107).  
 
In 2013, a Cochrane systematic review and meta-analysis on drug therapy for obstructive 
sleep apnea evaluated randomized, placebo controlled trials involving adult patients with 
OSA (116). The review included data of 30 trials evaluating 25 different drugs but noted that 
most of the studies were small with methodological limitations and that the overall quality of 
the available evidence was low. The review also concluded that there is currently insufficient 
evidence to recommend any systematic pharmacological treatment for OSA. Nevertheless, 
donezepil was identified as the most promising proposition at present and the authors 
suggested topical fluticasone in patients with co-existing rhinitis, as well as paroxetine, 
physostigmine, acetazolamide and eszopiclone as possible fields of future research. These 
studies however were not in elderly. 
 
Concerning the treatment of CSA in the elderly, we located one double-blind, randomized, 
cross-over trial that evaluated the use of acetazolamide in patients with systolic heart failure 
and Cheyne-Stokes breathing with an AHI above 15 (117). A total of 12 patients with a mean 
age of 66 years were treated for 6 nights with placebo or with 3.5 to 4 mg/kg acetazolamide 
and 30 mg potassium chloride, with the later given to compensate for acetazolamide-induced 
urinary potassium loss. Compared to the placebo condition, acetazolamide was associated 
with a mild to moderate reduction of the AHI, the central apnea index (CAI), and an increase 
in baseline oxygen and minimum saturation during REM and NREM sleep. 
Polysomnographic sleep parameters did not differ between acetazolamide and placebo.  
 
A further study evaluated the treatment of anemia in patients with congestive heart failure 
and anemia (118). In this open label study, 38 patients with a mean age of 76 years and 
hemoglobin levels below 12 g/dL were treated for 3 months with erythropoietin and 
intravenous iron up to a target level of 13 g/dL. The presence of sleep apnea was not an 
inclusion criteria, but 37 of 38 patients had an AHI greater 10 during nocturnal polygraphy 
with most of the apneas and hypopneas being central. Treatment of anemia was associated 
with a mild to moderate reduction of sleep-related breathing observed both for central and 
obstructive apneas. In addition, a reduction of Cheyne-Stokes breathing and an increase in 
minimal oxygen saturation during sleep was noted. Furthermore, daytime sleepiness 
improved after 3 months.  
For the treatment of OSA in elderly subjects, we located one double-blind, randomized, 
placebo-controlled trial that targeted OSA (119). In this trial, 23 patients (68-86 years) with 
mild to moderate Alzheimer´s disease and AHI > 5 were randomized to receive 3 months of 5 
mg donezepil or placebo. Compared to placebo, donezepil treatment improved the overall 
AHI and minimum oxygen saturation. In addition, REM sleep increased and the arousal index 
decreased. Finally, cognitive function assessed with the ADAS (Alzheimer Disease 
Assessment  Measures)-cog (cognition) score was improved in the donezepil treated group 
compared to the placebo group. 
 
A further double-blind, placebo-controlled, randomized trial (120) investigated whether the 
addition of ramelteon, a melatonin receptor agonist, improved sleep in elderly patients with 
sleep apnea and insomnia symptoms. Twenty-three patients (mean ages 74 and 70 years) 
received a standard 45 minute counselling session on sleep apnea and started APAP (Auto 
Positive Airway Pressure) treatment before being randomized to receive 8 mg of ramelteon 
(n = 8) or matching placebo (n = 15) for 4 weeks. Sleep onset latency during 
polysomnography was reduced in patients taking ramelteon while neither sleep efficiency,  
AHI, subjective sleep latency, nor sleep efficiency differed between groups subsequent to 
treatment. Also self-rated sleep quality, quality of life and daytime sleepiness was the same 
for patients treated with ramelteon vs. those treated with placebo. In addition, compliance 
with APAP treatment did not differ between groups and overall APAP adherence defined as 
≥ 4 h of use for ≥ 4 nights per week was 47%.  
 
Another drug that has been evaluated for the treatment in OSA is mirtazapine which had 
shown some effect on sleep-related breathing in randomized trials of adult patients (121). In 
a subsequent open label case series evaluating 15 mg mirtazapine at bedtime for 16 to 52 
days in elderly patients with  sleep apnea and refusal of CPAP reported mixed effects on 
breathing parameters (122). While mirtazapine improved sleep-related breathing to some 
extend in half of the patients, it also worsened sleep-related breathing in the other half of the 
patients, despite improving sleep in all patients.  
 
Based on the observation of a single case with moderate OSA and suspected ACE 
(Angiotesin Converting Enzyme) inhibitor induced cough with significant improvement of 
OSA after the ACE inhibitor was withdrawn and diuretics were introduced, a prospective 
case series included 9 patients with suspected OSA and on ACE inhibitor treatment, in whom 
ACE inhibitors were withdrawn and diuretics were introduced (hydrochlorothiazide at 25 mg/d 
combined with spironolactone at 25 mg/d) (123). The paper included data on a subgroup of 5 
patients with cough that had an average age of 65.4 years and was therefore included in the 
present review. In these patients, AHI decreased in all and exhaled nitric oxide, a marker of 
airway inflammation, decreased in parallel after discontinuation of ACE inhibitors. 
 
A recent crossover study in patients with COPD and overlap syndrome found no negative 
effects on nightly respiration in regards to AHI and Sa02  for the use of the orexin receptor 
antagonist and sleep drug survorexant. This study was age stratified using a different 
dosage, 30mg, for a patient group over 65years of age (124).   
 
Other case reports have suggested value of topiramate, aripiprazole, and selenium (125-127) 
in the treatment of sleep apnea. 
 
Summary 
In summary, large controlled studies on drug therapy of sleep-related breathing disorders in 
the elderly are still lacking. Two drugs that have received support from the results of smaller 
randomised trials are donezepil for the treatment of OSA and acetazolamide for the 
treatment of CSA. Both drugs have been shown to be effective in the treatment of sleep-
related breathing disorders in an elderly population with mild (acetazolamide) or moderate 
(donezepil) effects. In addition, there is some indication that improvement of co-morbid 
conditions in elderly patients with sleep-related breathing disorders may show some benefit 
also for breathing disorders during sleep as observed for correcting anemia in patients with 
CHF and anemia in an open label trial.  
 
 
 
Recommendations on the expert consensus level 
1. Due to insufficient data, positional treatment cannot be recommended as treatment 
for OSA in the elderly. GRADE: Strong 
2. More research is needed on the long-term effectiveness of drug therapy for the 
treatment of sleep-related breathing disorders in the elderly. At this point in time, no 
recommendation for drug therapy to treat SDB in the elderly can be given. 
3. Acetazolamide might alleviate Cheynes Stokes breathing in elderly patients with heart 
failure but further randomized controlled studies would be needed and side effects in 
long term treatment investigated to make recommendations. 
4. Drugs used to treat dementia, such as donezipil, melatoninergic drugs such as 
ramelton and agomelatine, and mirtazepin, erythropoietin, ace inhibitors and others 
can help to alleviate clinical symptoms of comorbidities coming with SDB but can 
currently not be recommended for the treatment of SDB in the elderly. GRADE:Weak 
5. Clinicians should be aware that several drugs may aggrevate sleep apnea. GRADE: 
Strong 
 
Supplemental Oxygen 
Only two papers (one observational study and one case report, evidence level 3) were 
identified which fit the selection criteria and addressed the effects of oxygen treatment on 
functional outcomes in older or frail people with SDB. They are presented in Table 6. None of 
the studies was age-stratified. 
 Intermittent nocturnal hypoxemia (INH) is a frequent consequence of both central and 
obstructive sleep apnea. INH is associated with cognitive (128-131) and functional (132) 
impairments. A large epidemiological study showed that INH rather than the number of 
apnoeic events per se doubled the risk of dementia in previously non-demented older 
community dwelling persons over a follow up period of four years (133). In a study of geriatric 
patients admitted for rehabilitation, INH was associated with functional impairment in a dose 
response relationship. However, as polysomnography was not performed, apnea frequency 
and sleep fragmentation could not be ruled out as additional factors (134). Nocturnal 
hypoxemia increases sympathetic activity and may contribute to cardiovascular 
complications of SDB such as hypertension and arrhythmias (135). Oxygen supplementation 
might therefore be effective in improving symptoms and complications of sleep apnoea, even 
if it does not directly address the airway obstruction. At least one case report suggests 
benefit of nocturnal O2 administration (136).  
 
One observational study included 200 consecutive geriatric in-patients with severe SDB 
defined as an ODI (oxygen desaturation index) > 30 events per hour. Each subject was first 
offered PAP therapy, and then offered nocturnal oxygen therapy at a rate of 3 L/min via nasal 
tubes as a second choice if they refused PAP. The mean age was 81±7 years. Twenty-two 
patients (11%) accepted PAP, 42 (21%) accepted oxygen supplementation, and 136 (68%) 
refused either treatment. Baseline functional status (Barthel index) was 48, 39, and 42 for 
PAP accepters, oxygen accepters and treatment refusers, and improved by 7, 22, and 24 
points respectively by discharge. There was no difference in the level of improvement 
between oxygen and PAP, and regression analysis showed that oxygen supplementation 
was independently associated with functional improvement (137). 
 
The information retrieved from this systematic review alone is clearly insufficient to inform 
guidelines on oxygen treatment in for OSA in the older or frail person. We have therefore 
also adduced evidence from studies in younger populations and evidence form trials which 
reported the effect of oxygen on OSA itself, rather than from wider functional outcomes.  
 
A recent meta-analysis of oxygen supplementation in younger and middle aged subjects with 
obstructive sleep apnea identified 14 randomized controlled trials including a total number of 
359 patients (138). The sample size of the individual studies included was small, ranging 
from n=8 to n=63, and dose and duration of oxygen supplementation varied between studies 
making comparisons difficult. Only 10 studies reported the effect of oxygen treatment on the 
extent and severity of OSA itself, while five also reported functional outcomes (e.g., daytime 
sleepiness, depression). Oxygen supplementation significantly improved nocturnal oxygen 
saturation, and led to a small but overall non-significant reduction in apnea frequency. 
However, oxygen supplementation also increased the duration of apneas in 3/5 
observational studies and in a larger comparison between oxygen versus CPAP with blood 
pressure (BP) as outcome CPAP had a clear advantage in decreasing BP over oxygen alone 
(139). 
 
Functional outcomes were reported in five studies. Of these, one showed an improvement of 
depressive symptoms and sleepiness with oxygen therapy (140), one a reduction in 
cardiovascular events (141), and two reductions in daytime somnolence (142,143). The 
largest study, however, showed no improvement of daytime somnolence with oxygen, but 
significant improvement with PAP (139).  
The increase of apnea duration, even in the absence of hypoxia, can lead to metabolic 
acidosis, and an increase in sympathetic activation (144), which could at least theoretically 
increase cardiovascular complications. This has not been observed in the meta-analysis or in 
the two studies in this systematic review, but could be a potential risk. This should be 
addressed formally in future studies of the effect of oxygen supplementation in OSA in older 
adults. 
 
Summary 
In conclusion, oxygen supplementation in subjects with sleep apnea and intolerance of PAP 
treatment seems rational, since oxygen supplementation corrects hypoxemia as well as PAP 
and has a minor, but non-significant beneficial effect on apnea frequency. Taking into 
account the high number of older subjects affected with sleep disordered breathing (4) and 
the high rate of intolerance of PAP treatment (145), randomized controlled trials in 
community dwelling and nursing home older people are warranted. Such trials should assess 
the effectiveness of oxygen supplementation in older people with sleep apnea and refusal of 
PAP treatment. They should also include determination of potential metabolic consequences 
such as acidosis, and functional outcomes such as the ability to perform activity of daily 
living, cognitive status, quality of life, the frequency of nursing home placement, and 
mortality. Only then the importance of oxygen therapy can be assessed unambiguously. 
Currently, this therapy should be considered as experimental. 
 
Recommendations on the expert consensus level:  
1. Oxygen treatment should not be used routinely for the treatment of obstructive sleep 
apnea in older persons. GRADE: strong 
2. In older, frail or demented patients who refuse PAP, oxygen treatment may be 
considered, but blood gases should be checked to exclude metabolic acidosis. 
GRADE: weak 
3.  Randomized controlled trials of oxygen treatment in this patient group with functional 
outcome measures are needed to inform treatment guidelines. 
 
DISCUSSION 
To our knowledge, this is the first systematic review of original studies addressing the treatment 
of sleep disordered breathing in the elderly. It is also the first publication of an expert consensus 
on SDB treatment in older or frail patients.  
 
Over the time frame of almost twelve years there were surprisingly few studies examining 
treatment of SDB in older adults and even fewer in frail older adults despite the large geriatric 
population and the high prevalence for SDB in this group. Studies of the management of OSA in 
the older patient population are rarely stratified for age. Studies which did include age 
stratification in SDB treatment mainly focused on the middle aged and younger patient groups. 
Had more studies in larger cohorts with a number of older patients included age stratification, a 
more advanced meta-analysis of data in the elderly would have been possible.Therefore one 
recommendation of the panel is to retrospectively age stratify SDB treatment trials and publish 
this sub data set, as in the Swedish oral appliance data set (69). In addition, new studies should 
also include age stratification in their analyses. Beyond stratification per se, formal analyses 
should examine to what extend age may be an effect modifier of treatment benefit. 
 
It is unclear why there are so few publications on the treatment of SDB in the geriatric population 
and why there are few larger randomized controlled trials, although there are a large number of 
epidemiological studies of prevalence of SDB in the elderly. Reasons could include a higher 
refusal rate for PAP treatment by older persons, perhaps also influenced by views of their 
younger relatives. However, if an old person does accept PAP, compliance is good. This low 
rate would result in a lower number of treated older adutls to be included in studies. Staff in 
regular sleep laboratories do not specialize in geriatric patients and therefore may not be able to 
cope with the extended nursing needs of the elderly, and especially frail elderly (4,19). Home 
testing of geriatric patients might make these studies more feasible.     
 
There are still few studies on frail elderly although they have most certain an even higher 
prevalence of SDB and might benefit from treatment. Reasons for this have been pinpointed 
above. More randomized controlled trials in geriatric patients with dementia are needed to 
determine if PAP in patients with dementia, improves cognitive function as in in middle aged or 
non-frail older patient populations.  
However, in addition to the still limited number of publications to date, it is obvious that the topic 
of geriatric sleep medicine is gaining more and more attention. The number of publications 
concerning elderly SDB patients just in the last year has expanded substantially compared to the 
years before. This also includes publications about therapy of SDB in frail elderly as presented 
here. Further recent epidemiologic publications with several hundred elderly subjects combined 
contain mainly data about the link between SDB in the elderly and a rapid cognitive decline (146-
148). One very recent publication encompassing a registry of of more than 25,000 OSA patients 
in Denmark followed up over more than ten years presents age stratified data comparing the 
survival rate of PAP users to OSA patients who were for various reasons not treated with PAP 
(149). The protective effect of PAP appeared particularly strong in older men >60yrs of age. 
Elderly women may not derive comparable benefit from PAP treatment relative to men. The 
reasons for this gender difference are not clear yet.  
 
A limitation of this expert consensus panel is that clinical recommendations are based on a low 
number of trials with high evidence levels. Also, as with all expert panels, personal bias cannot 
be excluded. Experts from outside the Americas and Europe were not part of the panel. 
Therefore the recommendations included here had to reach 100% agreement among the expert 
panel. This is the reason that recommendations for the treatment of SDB in geriatric patients at 
the moment do not differ much from principle of practice parameters for the treatment of SDB in 
all age groups (150). 
 
In summary, the individual recommendations are listed within each section, but the common 
theme is that more randomized controlled studies are needed in geriatric and frail elderly 
patients with SDB as comparable in other fields of general internal medicine (151). 
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